- Q3 2026 EPS at $(1.63) compared to $0.94 in the prior year period
- Cash and cash equivalents dropped to $17.5M from $45.8M at year-end 2025
- Cash runway projected only through Q1 2027, raising near-term dilution risk
Bearish AI Sentiment (-6.5 / 10)
Signal #128788 · SEC 8-K
$MCRB SEC Filing Alert & Real-Time AI Stock Impact Analysis
Public T0 SEO entry. Full AI score & bullets unlock after 4 hours (VIP: instant).
FAQ: $MCRB filing catalyst
Why did $MCRB trigger an AI stock catalyst alert?
$MCRB triggered a Stock Catalyst AI alert on 2026-11-04 00:00:00 UTC for a SEC 8-K filing (AI Score: -6.5/10). Headline: Seres Therapeutics Reports Q3 2026 Net Loss of $1.63 Per Share, Cash Runway Into Q1 2027. Key points: - Q3 2026 EPS at $(1.63) compared to $0.94 in the prior year period - Cash and cash equivalents dropped to $17.5M from $45.8M at year-end 2025 - Cash runway projected only through Q1 2027, raising near-term dilution risk
How did $MCRB stock react after the SEC filing?
After the SEC 8-K for $MCRB, observed market reaction: T0 price $1.96. Past moves do not guarantee future results.
Where can I get real-time $MCRB SEC filing alerts?
Stock Catalyst AI pushes real-time SEC 8-K alerts for $MCRB via Telegram and the VIP Web Terminal from €10/month.